All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

TP53 activators

TP53 activators

Inactive TP53 is associated with worse MDS prognosis and reduced response rates to treatment; thus, new therapeutic approaches are being developed that activate the TP53 signalling pathway. One promising agent from this category is APR-246, which induces apoptosis in tumor cells by restoring the transcriptional transactivation function of mutant p53.

|||